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Abstract Dapagliflozin, a selective inhibitor of the sodium glucose co-transporter type
2 (SGLT2) is in development for type 2 diabetes mellitus with Bristol-Myers
Squibb and AstraZeneca. It is currently undergoing phase III development
worldwide with regulatory submissions expected in the second half of 2010. This
review looks at the development history and scientific profile of this drug to date.
1. Introduction
Dapagliflozin, a once-daily oral antidiabetic, is a
selective inhibitor of the sodium glucose co-trans-
porter type 2 (SGLT2), in developmentwith Bristol-
Myers Squibb andAstraZeneca for the treatment of
type 2 diabetes mellitus. SGLT2 is a low affinity,
high-capacity transporter located in the brush-
border membrane of the early segment of the
proximal tubule of the kidney. The transporter is
responsible for 90% of the glucose reabsorbed by
the kidneys. SGLT2 inhibitors maintain blood glu-
cose levels by regulating the reabsorption of filtered
glucose. Dapagliflozin is in phase III development
in the US, Canada, Europe, Latin America, India
and South East Asia, and in phase II development
in Japan.
1.1. Company Agreements
In January 2007, Bristol-Myers Squibb and
AstraZeneca entered into a worldwide collabora-
tion agreement to develop and commercialize
dapagliflozin, and any additional SGLT2 or DPP
IV compounds to arise from the collaboration.
Under the terms of the agreement, AstraZeneca
paid Bristol-Myers Squibb an upfront payment
of $US100million, and will also make additional
milestone payments of up to $US650million
for the two compounds, and possible sales mile-
stones up to $US300million per product. Both
companies will jointly develop the clinical and
marketing strategy of the compounds. Astra-
Zeneca also agreed to fund the majority of
development costs from 2007 through 2009.
Bristol-Myers Squibb will manufacture both
compounds and book sales. The agreement in-
itially excluded all activities in Japan. However,
the agreement was expanded in December 2008 to
include development and commercialization of
dapagliflozin in Japan.[1,2]
1.2. Key Development Milestones
Dapagliflozin is undergoing phase III devel-
opment for the treatment of type 2 diabetes mel-
litus at multiple centers worldwide and is in phase
II clinical studies in Japan.[1] Regulatory sub-
missions in the EU and the US are expected in the
second half of 2010.
Bristol-Myers Squibb has completed a phase III
trial (NCT00643851) that evaluated the safety and
efficacy of dapagliflozin in combination with ex-
tended-release metformin as an initial therapy
compared with dapagliflozin or metformin alone
in approximately 600 patients with type 2 diabetes.
This randomized, double-blind, active controlled,
parallel-group study enrolled patients in the US,
Latin America, Philippines, South Korea and the
EU. Another phase III study (NCT00528372) is
assessing the safety and efficacy of dapagliflozin
monotherapy in treatment-naive patients with
type 2 diabetes who are not well controlled with
diet and exercise, or who have been on medication
for at least 24 weeks following diagnosis of type 2
diabetes. The study has completed recruitment of
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approximately 560 patients in the US, Canada,
Latin America (Mexico) and Europe (Russia).
Bristol-Myers Squibb is also conducting a phase
III study (NCT00528879) of dapagliflozin in 546
patients with type 2 diabetes in combination with
metformin in patients uncontrolled by metformin
alone. Study centers in the US, Canada and Latin
America have completed recruitment and interim
results were reported in October 2009.[3]
Bristol-Myers Squibb and AstraZeneca are
conducting a phase III study (NCT01031680) to
assess the safety and efficacy of dapagliflozin in
patients with type 2 diabetes, cardiovascular dis-
ease and hypertension. The study aims to enroll
940 patients in the US, Argentina, Canada,
Germany, Romania, Slovakia, Spain, Taiwan,
Turkey and Vietnam. Subjects will be random-
ized to receive dapagliflozin or placebo for
24 weeks plus a 28-week extension period.
A phase II/III, multicenter, randomized,
double-blind, placebo-controlled, parallel group
study (NCT00663260) is determining the safety,
pharmacokinetics and pharmacodynamics of
dapagliflozin in approximately 252 patients with
type 2 diabetes and moderate renal impairment.
The study is being conducted in theUS, Australia,
Canada, Israel, India, the EU, Latin America,
and Singapore and has completed recruitment.
In March 2008, the company completed a ran-
domized, double-blind, placebo-controlled, pilot,
phase II/III trial (NCT00357370) in 71 patients
with type 2 diabetes inadequately controlled by
insulin and one or two oral antidiabetics (met-
formin and/or pioglitazone or rosiglitazone). The
study was conducted in the US and Canada.
Results of this trial were reported in June 2009.[4]
Bristol-Myers Squibb completed a random-
ized, double-blind, parallel, phase IIb trial of
dapagliflozin (NCT00263276) in approximately
389 patientswith type 2 diabetes inCanada,Mexico,
Puerto Rico and the US. The study evaluated the
safety and efficacy of dapagliflozin in treatment-
naive patients who had inadequate glycemic control
on diet and exercise. Results have been reported.[5]
In September 2005, the company completed a phase
IIa study (NCT00162305) evaluating the safety,
pharmacokinetics and pharmacodynamics of da-
pagliflozin in patients with type 2 diabetes.
Table I. Features and properties table
Alternate names BMS 512148; BMS-512148
Originator Bristol-Myers Squibb
Licensee(s) AstraZeneca
Highest development phase III (Canada, EU, India, Israel, Latin America, South East Asia, US)
Active development-indications Type 2 diabetes mellitus
Class Pyrans, Small-molecules
Mechanism of action Sodium-glucose transporter 2 inhibitors
Chemical name (2S,3R,4R,5S,6R)-2- [4-Chloro-3-(4-ehoxybenzyl)phenyl] -6-(hydroxymethyl)tetrahydro-
2H-pyran-3,4,5-triol
Molecular formula C21 H25 Cl O6
CAS registry number 461432-26-8
Route of administration PO
Pharmacodynamics Induces glucose excretion; reduces plasma glucose levels; reduces bodyweight, prevents
development of diabetes, preserves beta cell mass; improves pancreatic islet morphology
in a rodent model of type 2 diabetes
ATC codes
WHO ATC code A10X (other drugs used in diabetes)
EphMRA ATC code A10X (other drugs used in diabetes)
Adverse events
Most frequent Genital tract infections
Occasional Back pain, Constipation, Diarrhea, Headache, Nasopharyngitis, Nausea, Respiratory tract
infections, Urinary frequency, Urinary tract infections
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In March 2010, Bristol-Myers Squibb and
AstraZeneca completed enrollment of 16 healthy
volunteers in a randomized, crossover, phase I
trial (NCT01072578) to assess the effect of
dapagliflozin on percent inhibition of glucose
re-absorption when dosed once daily (10mg once
daily) versus twice daily (5mg twice daily). The
trial is underway in Germany.
A completed phase I trial (NCT00538174) in
approximately 36 Japanese patients evaluated the
safety, pharmacokinetics and pharmacodyna-
mics of dapagliflozin administered for 14 days.
Additionally, Bristol-Myers Squibb completed a
phase I pharmacokinetic drug interaction study
(NCT00562250) of dapagliflozin and glimepiride in
approximately 11 healthy volunteers in Argentina.
Table II. History
Date Comment
7 April 2010 inThought analysis for type 2 diabetes mellitus updated
16 March 2010 AstraZeneca and Bristol-Myers Squibb complete enrollment in their phase I trial for type 2 diabetes mellitus in
Germany (PO, twice-daily dosing)
19 February 2010 Phase I clinical trials in type 2 diabetes mellitus in Germany (PO, twice-daily dosing)
2 October 2009 Efficacy and tolerability data from a phase II/III trial in type 2 diabetes mellitus presented at the 45th Annual
Meeting of the European Association for the Study of Diabetes (EASD-2009)[8]
2 October 2009 Efficacy and tolerability data from a phase III trial in type 2 diabetes mellitus presented at the 45th Annual
Meeting of the European Association for the Study of Diabetes (EASD-2009)[3,17]
2 October 2009 Final pharmacodynamics data from two preclinical studies in type 2 diabetes mellitus presented at the 45th
Annual Meeting of the European Association for the Study of Diabetes (EASD-2009)[13,14]
11 June 2009 Preclinical pharmacodynamics data in type 2 diabetes mellitus presented at the 91st Annual Meeting of the
Endocrine Society (ENDO-2009)[16]
7 June 2009 Efficacy and adverse events data from a phase II/III trial in type 2 diabetesmellitus presented at the 69th Annual
Scientific Sessions of the American Diabetes Association (ADA-2009)[4,11]
10 December 2008 Bristol-Myers Squibb and AstraZeneca expand their collaboration to develop and commercialize dapagliflozin
in Japan[1]
10 December 2008 Phase II clinical trials in type 2 diabetes mellitus in Japan (PO)
11 September 2008 Interim efficacy data from a phase III trial in type 2 diabetes presented at the 44th Annual Meeting of the
European Association for the Study of Diabetes (EASD-2008)[18,19]
10 June 2008 Final efficacy and adverse events data from phase II trials in type 2 diabetes mellitus presented at the 68th
Scientific Sessions of the American Diabetes Association (ADA-2008)[5,9]
31 October 2007 Data presented at the 2007 Annual Meeting of the North American Association for the Study of Obesity
(NAASO-2007) added to the diabetes pharmacodynamics section[15]
1 October 2007 Phase I clinical trials in type 2 diabetes mellitus in Japan (PO)
28 September 2007 Data presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD-
2007) added to the adverse events, pharmacokinetics and diabetes pharmacodynamics section[6,7]
11 September 2007 Phase III clinical trials in type 2 diabetes mellitus in the EU (PO)
26 July 2007 Phase III clinical trials in type 2 diabetes mellitus in Canada (PO)
26 July 2007 Phase III clinical trials in type 2 diabetes mellitus in India (PO)
26 July 2007 Phase III clinical trials in type 2 diabetes mellitus in Israel (PO)
26 July 2007 Phase III clinical trials in type 2 diabetes mellitus in Latin America (PO)
26 July 2007 Phase III clinical trials in type 2 diabetes mellitus in South-East Asia (PO)
26 July 2007 Phase III clinical trials in type 2 diabetes mellitus in the US (PO)
2 July 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007) added to the
adverse events and diabetes therapeutic trials sections[10]
15 November 2006 Phase II clinical trials in type 2 diabetes mellitus in the US (unspecified route)
23 November 2004 New profile
23 November 2004 Phase I/II clinical trials in type 2 diabetes mellitus in the US (unspecified route)
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A phase I trial (NCT00726505), which was to
characterize the kinetics of renal glucose re-
absorption in response to dapagliflozin, in heal-
thy subjects and patients with type 2 diabetes
mellitus in the US, was terminated. The reason of
termination was not disclosed.
1.3 Patent Information
The US Patent and Trademark Office has is-
sued a patent covering the composition of matter
which will expire in 2020.
2. Scientific Summary
2.1 Pharmacokinetics
Phase I: In a multiple-dose escalation (2.5–
100mg) trial in 40 healthy volunteers, dapagli-
flozin exposure (area under the concentration-
time curve [AUC]) increased dose proportionally.
An accumulation index of approximately 1.25
was observed with repeat daily dosing. The mean
daily amount of glucose eliminated in the urine
was similar after the first dose and after 14 days.
Cumulative 24-hour urine glucose excretion after
2.5 and 10mg dapagliflozin was approximately
50% and 70% of that excreted after doses ‡20mg,
respectively.[6]
In a single-dose escalation (2.5–500mg) trial in
64 healthy volunteers, the maximum concentra-
tion (Cmax) increased slightly less after an over-
night fast compared with that after a high-fat
breakfast. In the fasted state, the AUC from time
zero to infinity (AUCinf) increased slightly more
than proportionally with the dapagliflozin dose.
After a high-fat breakfast, the median time to
Cmax (tmax) was delayed by 2.5 hours, geometric
mean Cmax was 39% lower, and AUCinf was 7%
lower.[7]
2.2 Adverse Events
Phase III: Dapagliflozin, as adjunctive ther-
apy to metformin, was generally well tolerated in
a 24-week, randomized, phase III trial in patients
with type 2 diabetes who were inadequately con-
trolled with metformin alone. The rates of ad-
verse events overall were 89%, 95% and 98% in
patients who received dapagliflozin 2.5, 5 or
10mg, respectively, compared with 88% in those
who received placebo. Specifically, the incidence
of urinary tract infections was not significantly
different between the dapagliflozin 2.5, 5 and
10mg groups and the placebo group (4.4%, 7.3%
and 8.1% vs 8.0%, respectively). Rates of genital
infections were higher in the dapagliflozin 2.5, 5
and 10mg arms than the placebo arm (8.0%,
13.1% and 8.9% vs 5.1%, respectively), but these
events were mild or moderate in severity and did
not result in treatment discontinuation. Dapag-
liflozin was not associated with any clinically
significant electrolyte level increases or changes
in renal function. Dapagliflozin decreased blood
pressure (BP) to a greater extent than placebo
(systolic BP -3.1 to -5.9 vs -0.3mmHg and dia-
stolic BP -2.1 to -2.7 vs -0.4mmHg); although
there were no cases of hypotension. Hypogly-
cemic events occurred with a similar frequency in
the dapagliflozin 2.5, 5 and 10mg and groups
(2.2%, 3.6% and 3.7% vs 2.9% of patients, re-
spectively), but did not lead to study withdrawal.[3]
Phase II/III: Adverse events were reported at
similar rates across the dapagliflozin treatment
arms and the placebo group, in a 12-week trial in
71 patients with type 2 diabetes. Patients were
Table III. Forecasts
InThought Probability of Approval
Indication Approval Date Estimate inThought Approvability Index Last Update
Type 2 diabetes mellitus 5 Jan 2012 65% 7 Apr 2010
InThought Worldwide Revenuea
Indication 2010 2011 2012 2013 2014 2015 2016 2017 Last Update
Type 2 diabetes mellitus 0 0 129 485 1012 1526 1620 1718 7 Apr 2010
a All numbers in $US millions.
50 Adis R&D Profile
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (1)
randomized to dapagliflozin 10mg, dapagliflozin
20mg or placebo, in addition to insulin and one
or two anti-diabetes medications (metformin
and/or pioglitazone or rosiglitazone). The num-
bers of patients experiencing ‡1 adverse event for
dapagliflozin 10mg, dapagliflozin 20mg and
placebo, were 18/24, 16/24 and 15/23, respective-
ly. The most commonly reported (‡5% overall)
adverse events for dapagliflozin 10mg, 20mg
and placebo were: urinary frequency, back pain,
nasopharyngitis, nausea, headache and upper
respiratory tract infection. One urinary tract in-
fection and five genital tract infections occurred
in the dapagliflozin 20mg group, and one genital
tract infection occurred in the placebo group. The
number of reported hypoglycemic events was
seven for dapagliflozin 10mg, six for dapagli-
flozin 20mg and three for placebo. There was no
occurrence of major hypoglycemia.[4,8]
Phase II: The tolerability of dapagliflozin was
examined in a 12-week, phase IIb trial in 389
treatment-naive patients with type 2 diabetes.
Patients were randomized to receive either 2.5, 5,
10, 20 or 50mg of dapagliflozin, metformin 750mg
(titrated up to 1500mg) or placebo, once daily.
The most common adverse events in dapagliflozin
recipients were urinary tract infection, nausea,
dizziness, headache, fatigue, back pain and naso-
pharyngitis. Hypoglycemia was reported at a
frequency similar to that for metformin, but there
were no documented glucose levels of £50mg/dL.
There were no clinically meaningful changes in
serum sodium, potassium, calcium or creatine, or
urinary calcium noted. Serum uric acid declined by
1.0mg/dL with all dapagliflozin doses tested.[9]
A phase IIa study showed no serious adverse
events or treatment discontinuations due to
adverse events following treatment with dapagli-
flozin and metformin in patients with type 2 dia-
betes. This 14-day, randomized study involved
47 patients who received dapagliflozin 5, 25, 100mg
or placebo, once daily. Metformin therapy was
continued in patients who were receiving already
receiving treatment upon entry into the study.
Adverse events occurred with similar frequency
in subjects receiving dapagliflozin or placebo.
The most frequently reported adverse events were
constipation, nausea and diarrhea.[10]
Polyuria and pollakiuria were reported by
1.4% of subjects in the dapagliflozin groups (2.5,
5, 10, 20 and 50mg), in a phase II study including
389 treatment-naive patients with type 2 diabetes.
There were no reports of nocturia.[5]
Phase I: Dapagliflozin up to 150mg did not
prolong the corrected QT (QTc) interval in 50
healthy male volunteers.[11]
In a multiple dose escalation (2.5–100mg) trial
in 40 healthy volunteers, 24 adverse events oc-
curred in 16 subjects, 36.7% in the dapagliflozin
group and 50% in the placebo group. All events
were mild to moderate in intensity and the most
common was rash, which occurred in five sub-
jects. Dapagliflozin had no apparent effect on
renal safety markers or the QTc interval.[6]
In a single-dose escalation trial (2.5–500mg) in
64 healthy volunteers, 22 adverse events occurred
in 14 subjects, 21% in the dapagliflozin group and
25% in the placebo group. These were mild to
moderate in intensity. A total of 38 subjects ex-
perienced 49 laboratory abnormalities, including
11 hematological, seven blood chemistry varia-
tions and 31 cases of elevated urinary glucose.[7]
2.3 Pharmacodynamics
2.3.1 Diabetes Mellitus
Phase I: In a multiple-dose escalation
(2.5–100mg) trial in 40 healthy volunteers, there
were no apparent differences between dapagli-
flozin and placebo in urinary excretion of mag-
nesium, amino acids, calcium, chloride, oxalate,
potassium, phosphate, sodium, uric acid, NAG
and b2-MG.[6]
Preclinical: Dapagliflozin reduced the loss of
pancreatic function in the high fat fed female
ZDF rats with established hyperglycemia. The
compound reduced further progression of hyper-
glycemia and reduced the requirement for insulin
to control blood glucose thus preserving beta cell
function.[12]
Similarly, in a model of rapid beta cell loss in
male ZDF rats, dapagliflozin 1mg/kg once daily
for 5 weeks prevented the development of dia-
betes, did not increase bodyweight and preserved
beta cell function in a rodent model of type 2
diabetes.[13]
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Data from the study evaluating the effect of da-
pagliflozin on pancreatic islet morphology in obese
female ZDF rats showed that after once daily dose
of 1mg/kg for up to 34 days, the beta cellmass in the
lean, obese vehicle and dapagliflozin obese groups
were 0.68%, 1.15% and 1.49% of total cell count,
respectively. Dapagliflozin also markedly improved
islet morphology assessment by 2.3-fold (p< 0.05)
compared with obese vehicle control group. The
insulin staining intensity of islets after dapagliflozin
was elevated 2.2-fold (p< 0.05) compared with
obese vehicle-treated animals to the extent that there
were no detectable differences between dapagliflozin
and lean animal control groups.[14]
In diabetic rats, dapagliflozin acutely induced
renal glucose excretion at doses ranging from 0.01
to 1.0mg/kg of bodyweight without inducing hypo-
glycemia. Additionally, as early as 2 hours after a
single oral dose, there was a significant reduction in
plasma glucose levels in diabetic rats treated with
dapagliflozin, at doses of 0.1 and 1.0mg/kg, com-
pared with untreated diabetic rats.[10]
Treatment with dapagliflozin for 25 days re-
duced bodyweight in non-diabetic, diet induced
obese rats. Significant weight loss was observed
with all doses (0.5–5mg/kg), which was a function
of reduced adiposity. Dapagliflozin increased
urine glucose concentration, total urine glucose
and urine volume. There was also an observed
increase in water and food consumption.[15]
In db/db mice and high fat diet-induced obese
(DIO) mice, acute and chronic treatment with
dapagliflozin resulted in complete normalization
of ambient and fasted glucose levels, without
causing hypoglycemia. Chronic treatment with
dapagliflozin increased insulin content in islets.
Acute and chronic treatment of normoglycemic
DIO mice did not significantly affect glucose le-
vels, in contrast to db/db mice. Furthermore, the
total bodyweight did not change in dapagliflozin-
treated DIO mice despite a significant increase in
food and water intake.[16]
2.4 Therapeutic Trials
2.4.1 Diabetes
Phase III: A phase III randomized trial
(NCT00528879) met its primary endpoint of sig-
nificant reductions in glycosylated hemoglobin
(HbA1c) levels with 24 weeks of treatment with
dapagliflozin in addition to metformin, com-
pared with placebo and metformin, in patients
with type 2 diabetes mellitus who were in-
adequately controlled with metformin alone
(n = 546). Patients received either dapagliflozin
2.5, 5, 10 or placebo, in addition to metformin at
a dosage of at least 1500mg/day. At 24 weeks, the
mean changes from baseline in HbA1c levels were
significantly greater in the dapagliflozin 2.5, 5
and 10mg groups (-0.67%, -0.70% and -0.84%,
respectively) than in the placebo group (-0.30%).
Mean reductions in fasting plasma glucose (FPG)
were also significantly greater in the dapagliflozin
groups (-17.8, -21.5 and -23.5mg/dL, respect-
ively) than in the placebo group (-6.0mg/dL).
The proportion of patients who achieved an
HbA1c level of <7% at 24 weeks was significantly
greater in the dapagliflozin 5 and 10mg arms,
compared with the placebo arm (37.5% and
40.6% vs 25.9%), but the difference between
dapagliflozin 2.5mg and placebo was not signif-
icant for this endpoint. Significantly greater de-
creases in bodyweight were observed in all three
dapagliflozin groups, compared with the placebo
group.[3,17]
Sustained increases in urinary glucose excretion
were observed in dapagliflozin-treated patients
with type 2 diabetes enrolled in a phase III trial
(n = 389). A higher proportion of patients in
each of the dapagliflozin groups experienced a
5% reduction in bodyweight compared with pla-
cebo. There were small dose-related increases in
24-hour urine volume observed in the dapagli-
flozin groups (from 107 to 470mL in the 2.5 and
50mg/day groups) compared with reduction of
112 and 96mL in the placebo and metformin
groups, respectively. Dapagliflozin had no appar-
ent effect on appetite, as assessed using a visual
analogue scale.[18]
Dapagliflozin, at doses of 2.5, 5, 10, 20 and
50mg/day, improved glycemic control in treat-
ment-naive patients with type 2 diabetes enrolled
in a phase III trial (n = 389). All doses of da-
pagliflozin were associated with significantly
greater reductions in the proportion of HbA1c
than placebo at 12 weeks; the four highest doses
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also resulted in significantly greater reductions
than placebo in fasting plasma glucose, and
postprandial glucose measures reduced to a
greater extent with dapagliflozin than placebo.[19]
Phase II/III: Results from a 12-week, double-
blind trial demonstrated that dapagliflozin
produced greater improvements across all key
glycemic measures studied, in patients with
type 2 diabetes who were treated with high doses
of insulin and commonly used oral anti-diabetes
medications (OADs), compared with placebo
(placebo plus OADs plus insulin). The trial en-
rolled 71 patients who were inadequately con-
trolled by insulin and one or two baseline OADs
(metformin and/or pioglitazone or rosiglitazone).
Patients were randomized to dapagliflozin 10mg,
dapagliflozin 20mg or placebo, given once daily.
At 12 weeks, the adjusted mean decreases in
HbA1c from baseline were 0.61% in the dapagli-
flozin 10mg group and 0.69% in the dapagliflozin
20mg group, compared with an increase of 0.09%
for placebo. The percentage of patients that
achieved HbA1c of <7% at 12 weeks was 13% for
dapagliflozin 10mg and 4.3% for dapagliflozin
20mg, compared with 5.3% for placebo. The
percentage of patients that achieved HbA1c de-
crease from baseline of ‡0.5%was 65.2% for both
the dapagliflozin groups, compared with 15.8%
for placebo. The change from baseline in fasting
plasma glucose at 12 weeks was +2.4mg/dL for
dapagliflozin 10mg and -9.6mg/dL for dapagli-
flozin 20mg, compared with +17.8mg/dL for
placebo. Decreases in bodyweight were 4.51 kg,
4.3 kg and 1.88 kg in the dapagliflozin 10mg,
20mg and placebo groups, respectively.[4,8]
Phase II: The efficacy of dapagliflozin was
examined in a 12-week, phase IIb trial in 389
treatment-naive patients in type 2 diabetes.
Patients were assigned to receive either 2.5, 5, 10,
20 or 50mg of dapagliflozin, metformin 750mg
(titrated up to 1500mg) or placebo, once daily.
All doses of dapagliflozin were associated with
significantly (p < 0.01) greater reductions in
HbA1c than placebo. The change from baseline in
HbA1c was -0.71%, -0.90%, -0.18% and -0.73%
in recipients of dapagliflozin 2.5 and 50mg,
placebo and metformin, respectively. The four
highest doses of dapagliflozin were also asso-
ciated with significantly (p < 0.01) greater reduc-
tions in FPG than placebo. The change from
baseline in FPG was -19.3, -30.5, -5.8 and
-18.0mg/dL in recipients of dapagliflozin 5mg
and 50mg, placebo and metformin, respectively.
Postprandial glucose (PPG) measures were also
reduced to a greater extent with dapagliflozin
than with placebo. Dapagliflozin also increased
mean glucosuria values over 12 weeks, to
51.8–85.0 g/day, while metformin and placebo
values were 5.6 and 5.7 g/day, respectively. Mean
percent bodyweight reductions were 2.7–3.4%,
1.7% and 1.2%, and reductions in body mass in-
dex values were 0.9–1.1, 0.5 and 0.3 for the
dapagliflozin, metformin and placebo arms, re-
spectively. Small dose-related mean 24-hour
urine volume increases were seen at week 12 in the
dapagliflozin groups, and dapagliflozin did not
appear to affect appetite. Statistical comparisons
were not applied to the metformin arm.[5,9]
A phase IIa study showed positive results with
dapagliflozin in the treatment of patients with
type 2 diabetes. Dapagliflozin 5, 25 and 100mg
doses were all associated with significant reduc-
tions in fasting serum glucose on day 13, com-
pared with baseline (reductions of 14.5%, 17.3%
and 21.9%, respectively). Additionally, placebo
was associated with a 6.3% reduction in fasting
serum glucose, over this time. This 14-day, ran-
domized study involved 47 patients with type 2
diabetes who received dapagliflozin 5, 25, 100mg,
or placebo, once-daily; metformin therapy was
continued in patients who were already receiving
treatment upon entry into the study.[10]
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